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ABSTRACT 
 
This study examined the effects of resistant starch in a high fat diet (28% of energy) on 
body weight, abdominal fat, cecal weight and pH, serum gut peptide YY (PYY) and gene 
expression for PYY and proglucagon in male Sprague Dawley rats. Three groups of rats (8wk) 
were fed one of the following diets for ten wks: energy control (EC; 3.7 kcal/g), resistant starch 
(RS; 3.7 kcal/g) and fiber control (FC; 2.9 kcal/g). Results were classified as significant when 
p<0.05. The consumption of RS resulted in significant increases in cecal weight (full and empty), 
serum PYY, gene expression for PYY and proglucagon in cecum and significant decrease in pH 
in cecal contents compared to the other groups. However, the disemboweled body weight and 
abdominal fat for RS were not lower compared to the EC. In our previous studies, we observed 
that RS in a low fat diet (18% of energy), produced similar gut signaling, as in the current study, 
but reduced disemboweled body weight and abdominal fat compared to EC. The reason for the 
unexpected results needs further study. Since high fat diets have been shown to alter brain 
response to other satiety signals (leptin), a high fat diet might affect neuronal responses to PYY 
and GLP-1 signaling from the gut caused by dietary RS.  
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CHAPTER 1 
INTRODUCTION 
Obesity and overweight status continue to be leading public health concerns in the United 
States over several decades and its prevalence has been rapidly increasing in the United States, as 
well as other countries, over the past two decades (1,2). According to 2003-2004 data, 16% of 
US children and adolescents were at risk for overweight, 17.1% of US children and adolescents 
were overweight, 66.3% adults were overweight or obese and 32.2% adults were obese (2). Body 
mass index, expressed as weight/height2 (BMI; kg/m2), is commonly used to classify overweight 
status (BMI 25.0-29.9) and obesity (BMI greater than or equal to 30.0) among adults (age 20 
years and over) (3). Obesity has been associated with a relative increase in diabetes, 
cardiovascular disease, various cancers, respiratory disorders during sleep, gallbladder disease, 
and osteoarthritis (4). Adverse health effects of obesity justify the need to discover effective 
treatments, among them possible dietary treatments.  
It has been suggested that sufficient fiber in the diet will tend to prevent excessive food 
intake and fat accumulation by decreasing the caloric density of the diet, by slowing the rate of 
food ingestion, by increasing the effort involved in eating, by promoting intestinal satiety, and by 
interfering slightly with the efficiency of energy absorption (5). Resistant starches contain 
varying amounts of starch that resist amylase digestion in the small intestine and this resistant 
starch is fermented to short chain fatty acids (SCFA) by the microflora in the large intestine (6,7). 
When resistant starches are added to the diet, it is similar to adding fiber. Dietary resistant 
starches are reported to dilute caloric density, improve whole body insulin sensitivity, increase 
satiety, and increase lipid oxidation (8). Resistant starch in the diet may assist in the prevention 
and management of obesity via its potential effects on delaying the delivery of glucose as fuel 
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with subsequent fat utilization and appetite control benefits (9). Our research group has 
demonstrated reduced body fat in rats fed a low fat diet with resistant starch compared to rats fed 
an energy control diet (10).The results point to increased energy expenditure because energy 
intakes were not different.   
In order to design effective dietary treatments, it is essential to understand the physiology 
of appetite control and the pathophysiology of obesity. According to the first law of 
thermodynamics, energy equilibrium means the energy input in the form of food equals the 
energy expenditure through exercise, basal metabolism, thermogenesis and fat biosynthesis. The 
control of body weight concerns the control of adipose tissue and is concerned with the key role 
that is played by the hypothalamus. Ventromedial hypothalamus, a part of hypothalamus, plays a 
primary role in feeding behavior. In addition, the paraventricular nuclei (PVN) and arcuate 
nuclei (ARC) in the periventricular zone of the hypothalamus are the sites where multiple 
hormones, released from the gut and adipose tissue, converge to regulate food intake and energy 
expenditure. There are two distinct types of neurons in ARC that are important in control of food 
intake: (1) pro-opiomelanocortin neurons, which are activated by anorexigenic hormones, and (2) 
neurons, which are activated by orexigenic peptides. ARC plays a major physiological role in 
hunger and satiety sensation via orexigenic hormones (ghrelin and orexins) and anorexigenic 
hormones (cholecystokinin, peptide YY, glucagon-like peptide-1, oxyntomodulin, leptin and 
others). Thus, the signaling from the gut and adipose tissue before and after a meal reaches to 
specific receptors in the afferent (mostly vagal) nerves and the hypothalamic neurons, involved 
in adiposity signaling and the regulation of food intake, and maintains the energy balance (11).  
The gut-derived hormone, peptide YY (PYY), plays a role in modulating energy balance 
and adiposity through actions that regulate food intake, the efficiency of energy uptake, and 
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tissue metabolism of nutrients. PYY administration induced obese mice to have negative energy 
balance. This resulted from reduced food intake with a relative maintenance of mass-specific 
energy expenditure. The respiratory quotient (RQ) was lower indicating increased mobilization 
and oxidation of fat stores to help meet energy requirements which led to fat loss (12). 
 Oligofructose, another type of fermentable fiber- a non-starch polysaccharide, increases 
the mRNA expression of the proglucagon gene in the cecum and colon and blood levels of 
glucagon-like peptide 1 (GLP-1). Increases in GLP-1 are also involved in satiety and associated 
with reduced fat mass development and body weight (13).  
Current data from our lab demonstrated that dietary resistant starch increases the mRNA 
expression of PYY and proglucagon in the cecum of rats, and plasma PYY and GLP-1 (10,14). 
In addition SCFA were increased. Therefore, fermentable resistant starch may decrease the body 
fat via increases in SCFA in the large intestine, which appear to stimulate mRNA expression of 
PYY and proglucagon genes by large intestinal cells and increases in PYY and GLP-1 secretion 
by these cells. All of our lab group’s previous work has been done with low fat diets based on the 
fat level (18% of energy) of the AIN-93 diet (10,14).   
Objectives 
 The objective of the study was to examine the effects of resistant starch (RS) in a high fat 
diet (28% of energy) on body fat, body weight and gut signaling in rats. The specific objectives 
addressed by the study were the following: 
• To measure the body weights, abdominal, perirenal and epididymal fat pads, and the total 
body fat composition. 
• To determine the pH of the cecal contents and cecal weights. 
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• To measure the plasma PYY level, and gene expression for PYY and proglucagon in the 
cecum.  
Hypotheses 
The hypothesis of the study was that the RS in a high fat diet (28% of energy) will also 
increase gut signaling to reduce body fat as occurred in our earlier studies on resistant starch in a 
low fat diet (18% of energy). Specific hypotheses addressed by the study were the following: 
• The inclusion of RS in a high fat diet (28% of energy) will increase the gene expression 
of PYY and proglucagon, and plasma PYY levels in rats. 
• The inclusion of RS in a high fat diet (28% of energy) will decrease the body weight, 
abdominal fat, perirenal fat, epididymal fat and total percent body fat in rats. 
• The inclusion of RS in a high fat diet (28% of energy) will decrease the pH of the cecal 
contents and increase the cecal weights in rats. 
Assumptions 
• It is assumed that rats from the current study will be similar to rats used in the low fat 
studies and that all conditions for the studies will be similar. 
• It is assumed that rats will be weighed accurately and recorded correctly throughout the 
study. 
• It is assumed all assays will accurately assess in vivo conditions. 
Limitations 
• ARC neuropeptides were not assessed although the hypothalamus plays a role in energy 
balance. 
• An effect of resistant starch in low fat diets on gut signaling was not assessed in this 
study though done in our earlier studies. 
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• Effects of different types of fats on body weight and body fat were not examined. 
• This was an animal study and results may not be similar for human subjects. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Dietary Fiber 
The term “dietary fiber” coined by Hipsley, in 1953 is one of the most talked about 
nutrients for health promotion and disease prevention at this present time (15). In 1976, Trowell 
and co-workers defined dietary fiber as the digestion-resistant polysaccharides (mostly plant 
storage saccharides), such as gums, modified celluloses, mucilages, oligosaccharides, and pectins. 
This definition also includes cellulose, hemicellulose, lignin, gums, modified celluloses, 
mucilages, oligosaccharides, pectins, and associated minor substances, such as waxes, cutin, and 
suberin (15). The Association of Official Analytical Chemists (AOAC) in 1995 defined dietary 
fiber as the remnants of the edible part of plants and analogous carbohydrates that are resistant to 
digestion. It includes polysaccharides, cellulose, and lignin and associated plant substances (15). 
In this context, the Panel on Macronutrients (DRI) recently defined dietary fiber as the 
nondigestible carbohydrate and lignin that are intrinsic and intact in plants. Functional fibers are 
the isolated, nondigestible carbohydrates that have proven beneficial physiological effects in 
humans. Total fiber is the sum of dietary fiber and functional fiber (16). Many researchers also 
classify dietary fiber as insoluble dietary fibers which are known to promote bowel regularity; 
and soluble fibers which are known to reduce blood cholesterol and blood glucose (17). Dietary 
fibers are also classified as non-fermentable fibers and fermentable fibers by many research 
groups (18). The non-fermentable fibers increase the fecal bulk, decrease the transit time, help in 
carcinogen binding and bile salt binding and increase the viscosity (18). The fermentable fibers 
also pass the small intestine without being digested and then are fermented in the large intestine 
and produce short chain fatty acids (SCFAs) and decrease the pH (18). These SCFAs produced 
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in the large intestine after fermentation help in lowering blood cholesterol, restoring normal 
intestinal flora, inhibiting growth of harmful bacteria and reducing liver toxins, food intolerances 
and food borne allergies (19). Resistant starch, oligosaccharides, oligofructose, fructan, inulin, 
and β-glucan are a few examples of fermentable fibers, whereas cellulose, hemicellulose and 
methylcellulose are a few examples of non-fermentable fibers (18). Despite not having an exact 
definition and classification of dietary fiber, experts agree on one important thing - dietary fiber 
is an important weapon in the fight against heart disease, colon cancer, diabetes, and obesity. 
Resistant Starch  
 The term “resistant starch” was coined in 1982 by Englyst and his coworkers to describe 
a small fraction of starch that was resistant to hydrolysis by exhaustive amylase and pullulanase 
treatment in vitro, and  his group also confirmed that this same type of starch also resisted 
enzymatic hydrolysis in vivo using healthy ileostomy subjects (20,21).  Resistant starch (RS) is 
subdivided into 4 fractions, RS1, RS2, RS3 and RS4. RS1 is physically inaccessible to digestion 
and is entrapped in a non-digestible matrix, found mainly in whole grains and legumes. RS2 is 
mainly the ungelatinized starch granules found in raw potato starch, green banana and high 
amylose cornstarch. RS3 is the retrograded starch found mainly in cooked and cooled potatoes, 
bread, cornflakes and food products with repeated moist heat treatment. RS4 is chemically 
modified starch due to cross linking with chemical reagents, found in breads and cakes (6,20). 
Resistant starches are the non-digestible portion of the various types of foods and like fiber resist 
amylase digestion in the small intestine and are fermented by the microflora in the large intestine 
to short chain fatty acids (SCFA) which leads to a decrease in pH (6,7). The amount of resistant 
starch can vary depending on the degree of processing and time spent in small intestine prior to 
entry into large intestine. 
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The major SCFAs produced include butyrate, acetate and propionate, and it is believed 
that these SCFA in particular mediate many potential physiological effects such as improved 
glycemic and insulinaemic responses, improved bowel health, improved blood lipid profile, 
increased satiety and reduced energy intake, increased micronutrient absorption and 
thermogenesis (6,7). All these factors may be helpful in preventing diseases such as colorectal 
cancer, cardiovascular disease, osteoporosis and obesity and assist in the management of diabetes, 
impaired glucose tolerance, inflammatory bowel diseases, diverticulosis and constipation (6,7). 
Butyrate is the key short chain fatty acid which increases the secretion of gut peptides such as 
peptide YY (PYY) and glucagon like peptide 1 (GLP-1) through the ileal brake which in turn 
regulates food intake and increases satiety (22). 
PYY and GLP- 1 are mainly synthesized in the intestinal endocrine cells in response to 
the ingested nutrients. Glucose and fatty acids are the two major nutrients that influence PYY 
and GLP-1 secretion (14). Thus, our lab designed a study using male Sprague Dawley rats as a 
model to examine the gene expression patterns for PYY and proglucagon in the duodenum, 
jejunum, cecum and colon. Rats were randomly divided into 2 groups: control group fed a 
standard AIN-93G powdered diet and the resistant starch group. The diet of resistant starch fed 
rats was the same as the diet of the control group except that resistant starch was used to replace 
the regular starch. Rats were fed for 4 weeks. The results showed that resistant starch fed rats had 
higher gene expression for PYY and proglucagon in the cecum and colon compared to control 
rats. Interestingly, it was also found that the proglucagon and PYY gene expressions were 
unchanged in the jejunum and ileum by RS, but were increased in the cecum and colon, where 
the fermentation of RS occurred.  When cells of the surface layer of the cecum and colon were 
incubated with butyrate in vitro, the PYY and proglucagon gene expressions were also increased 
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in a dose dependent manner. Thus, it appears that the distal part of the gut senses the butyrate, a 
short chain fatty acid and up regulates the PYY and proglucagon gene expression (14). Our lab 
also recently reported at the Experimental Biology 2007 conference that dietary RS promotes a 
consistent elevation in plasma GLP-1 and PYY levels compared to the non-fermentable fiber diet 
(EC) in rats. RS-fed rats also had decreased body fat compared to the EC fed rats. Thus, this data 
strongly support our  hypothesis that RS fermentation stimulates GLP-1 and PYY expression in 
the gut (23).  
Retrograded amylose, an example of RS3, resists digestion and passes through the small 
intestine and enters the large bowel where it is fermented.  Retrograded amylose cornstarch was 
prepared by gelatinization of high amylose cornstarch, followed by storage at 1ºC for 48 hours 
for a rat study. Twenty four male Wistar rats were randomly divided into 2 groups. One group 
was fed a diet with retrograded amylose cornstarch and the other a control diet without resistant 
starch for the study of 14 days. The control diet was prepared by using standard AIN-93 
ingredients. The intra-cecal pH was measured by inserting a microelectrode through a small 
incision. The cecum was subsequently removed and the wet weights of both the collected cecal 
contents and rinsed tissue were recorded. Cecal size and contents were found to be greater in the 
resistant starch-fed rats, and cecal pH was significantly lower in resistant starch fed rats 
compared to the control group. This study confirmed that a substantial proportion of retrograded 
amylose from cornstarch escapes hydrolysis in the small intestine, and acts as a substrate for 
bacterial fermentation in the cecum (24). 
RS, a prebiotic, is a potential substrate for fermentation by the microbiota, and is capable 
of stimulating proliferation and activity of endogenous desirable bacteria. It is believed that RS 
shows its beneficial physiological effects by production of SCFA through fermentation (25). 
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Ninety six male Sprague-Dawley rats that were 5 weeks old were obtained and randomly divided 
into 8 experimental groups. Rats were fed experimental diets for 4 weeks. Rats had free access to 
water and were weighed weekly throughout the study. The experimental diets were based on the 
AIN-76 standard for purified diets for rats and mice and contained either low-RS or moderate-RS 
(10% Hi-maize 958).  Lactobacillus acidophilus, Bifidobactrium lactis and a combination of the 
2 cultures were added at a concentration of 1% each by weight to semi purified diets containing 
low-RS or moderate-RS at the expense of sucrose. The 8 experimental diets were low RS, low 
RS+ lactobacillus acidophilus, low RS+ Bifidobacterium lactis, low RS+lactobacillus 
acidophilus+Bifidobacterium lactis, moderate RS, moderate RS+ lactobacillus acidophilus, 
moderate RS+ Bifidobacterium lactis and  moderate RS+lactobacillus 
acidophilus+Bifidobacterium lactis. The feces and ceca were collected for analysis of SCFA and 
pH. The fecal pH of moderate RS groups with different bacteria cultures were not significantly 
different than low RS groups with different bacteria cultures, but moderate RS without any 
added culture had significantly lowered (p<0.05) fecal pH than low RS without added culture. 
The fecal SCFA contents were significantly higher (p<0.05) in all moderate RS groups compared 
to all low RS groups. All moderate RS groups had significantly higher (p<0.05) cecal SCFA 
content and lower pH (p<0.05) than all four low RS groups. Thus, at least 10% RS can influence 
the fermentation variables such as pH and SCFA concentrations both in the cecum and feces, and 
can act as a proper substrate for fermentation and also provide a right condition for bacterial 
action. (25). 
 Thirty Wistar rats that were 8 weeks old were used to study the effects of different forms 
of resistant potato starch (RS) on the SCFA production. The experimental diets were fed for 5 
months. The rats had an average initial body weight of 210g, and were adapted for 7 days to a 
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balanced basal diet containing 60% waxy maize starch devoid of any RS. Then rats were 
randomly divided into 3 groups each with 10 rats, and were fed diets containing their respective 
diets. Group 1 rats were fed a rapidly digestible waxy maize starch (basal diet: 0% RS), group 2 
rats were fed a mixture of 83.3% waxy maize starch (0% RS) and 16.7% native granular potato 
starch (60% RS), group 3 rats were fed a mixture of 33.3% waxy maize starch (0%RS) and 
66.7% modified retrograded potato starch (15% RS). The final RS content of 10% of the diets 
was calculated on the basis of raw potato starch and retrograded potato starch for the group 2 and 
group 3, respectively. At the end of the study, the feces and ceca were collected to examine the 
effects of 10% raw potato starch and 10% retrograded potato starch on SCFA production. It was 
found that group 3 rats had a significantly higher (p<0.05) concentration of cecal SCFA such as 
acetate, propionate and butyrate compared to both group 1 and 2 rats. Whereas, in the case of the 
fecal SCFA, only propionate was found higher (p<0.05) in group 3 rats compared to group 1 and 
2 rats. These results suggest that fermentation of retrograded potato starch produces higher 
SCFAs: butyrate, propionate and acetate compared to the raw potato starch (26). 
Non-starch polysaccharides, a type of carbohydrate with similar effects as RS, have 
slower digestion and absorption of carbohydrates in the small intestine and undergo fermentation 
in the colon. Fructooligosaccharides, oligofructose and xylooligosaccharides are a few examples 
of the indigestible and fermentable non-starch oligosaccharides. To evaluate the in vivo effects of 
the oligosaccharides on cecal and fecal short chain fatty acids, pH and total large bowel wet 
weight, fifty male Sprague Dawley rats were acclimatized with a purified powdered diet before 
starting the experiment. Rats were individually housed in a stainless steel cage and had free 
access to water. Fifty rats were randomly divided into 5 groups and fed 5 types of experimental 
diets for 14 days.  The five experimental diets were: control diet, control diet +5% 
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microcrystalline cellulose (5% CC), control diet +5% CC +6% fructooligosaccharides, control 
diet +5% CC + 6% oligofructose, and control diet +5% CC +6% xylooligosaccharides. It was 
found that total cecal SCFA pools were higher and pH was lower in rats fed the oligosaccharide 
containing diets compared with rats fed with control or cellulose diets. Cecal total weight was 
found higher in all oligosaccharide fed groups compared to the control and cellulose groups, 
whereas colonic total wet weight was significantly higher for only rats consuming 
xylooligosaccharides compared with other treatments. Thus, dietary fermentable, indigestible 
oligosaccharides produce SCFAs through fermentation that lead to lower pH in cecum and 
higher cecal weight (27). 
 These data demonstrated that resistant starch and other oligosaccharides that are 
fermented produce similar effects. Fermentation of oligosaccharides is also associated with an 
increase in the levels of certain gastrointestinal peptides (24). Resistant starch and 
oligosaccharides have additional gastrointestinal effects such as transfer of energetic molecules 
from the small to the large intestine, increased bulking effects and increased fecal excretion of 
energy (28). 
Resistant Starch and Body Fat  
To assess the effects of dietary resistant starch on abdominal fat and gene expressions of 
PYY and GLP-1, our lab conducted two studies. In the first study, thirty, 7-month- old female 
retired breeder rats were assigned to 3 diets treatment groups: control group (5% fiber, 3.6 
kcal/g), fermentable high amylose-resistant cornstarch (RS; 39.9% fiber, 33% RS, 3.2 kcal/g) 
group and non fermentable methylcellulose (MC; 37.5% fiber, 2.5 kcal/g) group. RS and MC 
groups were similar in their fiber levels. In the second study, thirty, 8-week-old male rats were 
randomly assigned to two diet treatment groups: resistant starch (RS; 3.3 kcal/g, 36.3% fiber, 
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29.7% RS) group and non fermentable cellulose energy control group (EC; 3.3 kcal/g, 15.7% 
fiber). The study was in three phases: 1, 3 and 5 weeks. The data was combined statistically 
within a factorial arrangement of treatments with diet and time as independent variables. In the 
first study, RS fed rats had higher serum levels of PYY and higher gene expressions for PYY and 
proglucagon in cecum and large intestine compared to the two control groups of rats. RS fed rats 
had lower pH of the cecal contents and higher cecum weights compared to the control and MC 
groups. RS rats had lower abdominal fat and disemboweled body weight compared to the control 
group but there was no difference in disemboweled body weight and abdominal fat between RS 
and MC group. At the end of study 2, RS fed rats had higher plasma levels of PYY and higher 
gene expressions for PYY and proglucagon in cecum compared to the EC fed rats. RS fed rats 
had lower disemboweled body weight, abdominal fat, pH of the cecal contents and higher cecum 
weights, weights of cecal contents, butyrate, propionate and acetate production in cecal contents 
compared to the EC group. All these results suggest that RS as a result of fermentation produces 
SCFA in the large intestine, which then leads to increases in gene expression of PYY and GLP-1. 
Study 2 demonstrated that when dietary energy is similar, effects of fermentation on reducing 
body fat and disemboweled body weight are observed (10). 
High-fat diets promote obesity by the mechanism of hyperphagia because more energy is 
consumed as a result of higher energy density of the diet. Current recommendations for the 
management of obesity include an increase in dietary fibers to dilute the energy density of the 
diet and control energy intake (13). Our lab group has demonstrated effects of dilution of dietary 
energy with non-fermentable fiber in a high fat diet (10,29). The effects of fermentation with a 
high fat diet need to be addressed. 
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Oligofructose (OFS), a fermentable fiber decreases the food intake and fat mass by 
increasing GLP-1 and possibly improving satiety. To examine the effect of OFS in a high fat diet 
on food intake modulation and proglucagon derived peptide and ghrelin levels, 12 male Wistar 
rats were randomly divided into two groups: high fat OFS diet with a metabolizable energy 
(MEV) of 4.1kcal/g and high fat control diet with MEV of 4.4kcal/g. At the end of the study, 
blood, cecum and colon samples were collected. The results showed that high fat OFS rats had 
lower body weight and energy intake (p<0.05) than high fat control rats. Also high fat OFS rats 
had significantly higher mRNA (p<0.05) expression for proglucagon in cecum and proximal 
colon. GLP-1 levels were found higher (p<0.05) and dipeptidyl peptidase IV (DPPIV) levels, an 
enzyme that degrades active GLP-1, were found lower (p<0.05) in portal circulation in high fat 
OFS rats. There was no change in plasma ghrelin concentration between the high fat OFS and 
high fat control group. Thus, the addition of OFS in the diet appears to protect against the 
promotion of energy intake, body weight gain, fat mass development induced by a high-fat diet 
by increasing the proglucagon mRNA in the cecum and the colon and portal concentration of 
GLP-1. However, the dietary energy density of the high fat control may also have a role in 
producing reported effects (13).  
To examine the relationship between the RS content in a meal and post absorptive fat 
oxidation, a study was conducted with 12 human subjects (5 males and 7 females). The subjects 
received four meals differing only in resistant starch (RS) content in random order, 
approximately four weeks apart. Meals contained 0%, 2.7%, 5.4%, or 10.7% RS as a percentage 
of total carbohydrate. Subjects were between 28 to 45 years old and had a BMI ranging from 20 
to 28.  It was observed that addition of 5.4% RS to the diet significantly decreased the respiratory 
quotient compared to the meals that contained 0%, 2.7% and 10.7% RS, indicating an increase in 
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fat oxidation. The consumption of 10.7% RS was not associated with increased fat oxidation. 
Thus, they suggest at higher RS consumption, only a portion of RS is fermented and the 
remainder passes through the colon as an insoluble fiber (8).  
Administration of PYY and GLP-1 Hormones 
PYY and GLP-1 are gastrointestinal-derived hormones that are released post-prandially 
in proportion to the amount of calories ingested. PYY reduces food intake and body weight and 
suppresses appetite when intravenously infused into rodents and humans. Circulating PYY 
concentrations increase after food ingestion and have been low in obese humans. Peripheral 
infusion of PYY [3-36] reduces the food intake, hunger sensation and body weight gain (12). 
Peripheral administration of GLP-1 also significantly reduces gastric emptying and food intake 
in both rodents and humans (30). These gastrointestinal hormones influence central nervous 
system feeding circuits via vagal–brainstem–hypothalamic pathways. To investigate the role of 
the vagal–brainstem–hypothalamic pathway in the mediation of the inhibitory effects of 
peripheral PYY [3–36] and GLP-1 on food intake, a study was conducted using male Wistar rats 
as the animal model. Rats had undergone either bilateral vagotomy or brain-stem hypothalamic 
pathway transectioning. The bilateral sub-diaphragmatic total truncal vagotomy was done by 
freeing the ventral and dorsal vagal trunks from the esophagus below the diaphragm, and then 
tying and cauterising to minimise nerve regeneration. Rats, while undergoing brainstem–
hypothalamic pathway transectioning were placed in a stereotaxic frame with the head fixed 2.4 
mm below the interaural line. A wire knife (Model 120, David Kopf Instruments) was lowered in 
the brain in a coronal plane, bilaterally 0.5 mm from the midline, 1 mm caudal to the lambdoidal 
suture and 8 mm ventral to the dura, and then rotated to extend the blade 1.5 mm laterally from 
the midline. The knife was then raised to 3 mm ventral to the dura before being retracted and 
 16
removed from the brain. Then food intake was measured after the administration of PYY [3-36] 
and GLP-1. The results showed that the effects of peripheral administration of both PYY [3–36] 
and GLP-1on food intake and activation of hypothalamic arcuate feeding neurons were abolished 
in rats that had undergone either bilateral sub-diaphragmatic total truncal vagotomy or 
brainstem–hypothalamic pathway transectioning. These findings suggest that the vagal–
brainstem–hypothalamic pathway plays a role in the effects of circulating PYY3–36 and GLP-1 
on food intake and may play a role in reducing body weight. The findings of the study also 
support the role of PYY and GLP-1 in food intake regulation (31). 
 The gut hormone fragment PYY [3–36] with the adipocyte hormone leptin reduces food 
intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a 
marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. A 
study was conducted to investigate whether obese subjects are resistant to the anorectic effects of 
PYY. Twelve healthy obese and 12 healthy lean subjects were recruited. The inclusion criteria 
for the study were BMI of 27 to 40 for the obese group and 17 to 23 for the lean group. The 
control and experimental groups received a 90-minute infusion of saline or PYY (total dose, 2 
nmol per square meter of body-surface area), respectively. Two hours after the termination of the 
infusion, the subjects were offered a buffet lunch with food in such excess that all appetites could 
be satisfied. The amounts of food and water were quantified preprandially and postprandially, 
and the caloric intake was calculated. Six hours after the infusion, plasma levels of PYY, ghrelin, 
insulin and leptin were measured. Results showed caloric intake during a buffet lunch offered, 
two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (p<0.001) 
and 31 percent in the lean subjects (p<0.001). PYY infusion resulted in a significant decrease in 
the cumulative 24-hour caloric intake in both obese and lean subjects.  
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Plasma levels of leptin and insulin were found significantly higher in the obese group and 
unaffected by PYY infusion. PYY infusion reduced the plasma levels of the appetite-stimulatory 
hormone ghrelin. Endogenous fasting and postprandial levels of PYY were found significantly 
lower in obese subjects (p<0.001) compared to the lean subjects. Furthermore, the fasting PYY 
levels were correlated negatively with the BMI (r=-0.84, p<0.001). These findings suggest that 
obese subjects are not resistant to the anorectic effects of PYY. Thus, low endogenous PYY 
levels in the obese subjects, suggest that PYY deficiency may contribute to the pathogenesis of 
obesity (32). 
The effect of the pharmaceutical administration of PYY [3-36] on body weight and 
adiposity in diet induced obese mice was determined. Obesity was induced in rats by high-fat 
feeding (58% of energy from fat, 16% from protein, 26% from carbohydrate) at 4 wk of age. 
Mice were fed this diet throughout the study. The experimental group received continuous PYY 
[3-36] administration whereas the control group received the vehicle dimethyl sulfide. The 
parameters, researchers measured, were the respiratory quotient (RQ), food intake, body weight 
and adiposity. Food intake (p<0.05) and body weight (p<0.001) were significantly reduced 
compared to the control group. The RQ of the light cycle was reduced significantly (p<0.001) 
throughout the study whereas the dark cycle RQ was only transiently decreased (p<0.001) 
compared to the control group. Epididymal fat pad weights in PYY [3-36]–treated mice were 
50% lower than in controls (p < 0.01). A negative energy balance after PYY [3-36] 
administration in diet-induced obese mice resulted from reduced food intake. Thus, fat loss and 
reduced RQ after the PYY [3-36] administration highlight the potential role of PYY[3-36] in 
driving increased mobilization of fat stores to help meet energy requirements (12). 
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Another research group also examined the endogenous postprandial PYY response and 
the effect of exogenous PYY [3–36] doses on satiety and food intake in human subjects. The 
human study included 20 obese and 20 normal-weight subjects. The obese volunteers had lower 
(p <0.001) fasting plasma PYY levels compared to the healthy subjects. Although a rise in 
plasma PYY levels in both obese and normal subjects was seen after having the meal, obese 
subjects had lower postprandial plasma PYY levels (p <0.05) than control subjects. The PYY [3-
36] infusion to humans showed a negative correlation between food intake and infused PYY [3-
36] concentration. However there was no correlation between the hunger sensation and PYY 
concentration. In another study researchers studied the effects of a high-fat (HF) and low-fat (LF) 
diet on plasma PYY in mice. The infusion of PYY [3-36] in mice significantly reduced the food 
intake in HF mice compared to the HF mice injected with saline. The HF mice without PYY [3-
36] infusion had both fasting and postprandial plasma PYY levels lower compared to the LF 
mice. Thus, the PYY release from the intestinal tract may be inhibited in the obese, leaving 
obese subjects with a functional deficiency in PYY-induced satiety (33). 
  GLP-1, another hormone, along with PYY and other possible hormones participates in 
the regulation of energy intake. To examine the effect of intravenously infused GLP-1 on 
subjective appetite sensations after an energy-fixed breakfast and on spontaneous energy intake 
at an ad libitum lunch, 20 young, healthy, normal weight men were recruited. It was a placebo-
controlled, randomized, double blinded study. Subjects were tested for 2 different occasions for 
the study, separated by at least 3 weeks but not more than 7 weeks. The breakfast consisted of 
yogurt, bread, butter, cheese, jam, kiwi fruit, orange juice, and water. Total available energy 
content of the meal was calculated to be 20% of each subject’s individual energy requirements in 
a day. The lunch was a homogeneous mixed hotpot consisting of pasta, minced meat, green 
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pepper, carrots, squash, onions, corn, and cream. For both meals, the distribution of energy was 
50% energy from carbohydrates, 37% energy from fat, and 13% energy from protein. Fifty 
pmol/kg body weight per hr of either saline or GLP-1 was infused simultaneously with initiation 
of the test meals. GLP-1 infusion enhanced satiety and fullness during breakfast when compared 
with the saline infused group (treatment effect: p <0.03). Furthermore, spontaneous energy 
intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline 
infusion (p <0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced 
energy intake and thus may play a physiological regulatory role in controlling appetite and 
energy intake (30). 
Exenatide and Body Weight Regulation 
Exenatide is a compound that exhibits activity similar to the naturally occurring gut 
hormone GLP-1. GLP-1 is released from cells in the gut in response to food ingestion and binds 
to pancreatic beta-cell receptors to stimulate the release of insulin. Exenatide administration 
mirrors many of the effects of GLP-1, which include glucose-dependent stimulation of insulin 
secretion, suppression of glucagon secretion, slowing of gastric emptying, reduced appetite and 
enhanced beta-cell function. In addition to positive therapeutic effects on fasting and 
postprandial glucose levels, exenatide treatment is also associated with progressive reductions in 
body weight. Exenatide is reported to enable patients with type 2 diabetes to achieve glycemic 
control and  promotes weight loss in obese subjects (34). Exenatide treatment in the amount of 
5pg per week for two years to type 2 diabetic subjects in a study also led to a decrease in 
glycosylated hemoglobin and body weight, suggesting its importance in glycemic control and 
body weight regulation (35). In another study, eight two week periods of adjunctive exenatide 
treatment in obese patients with type 2 diabetes also resulted in sustained reduction in 
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glycosylated hemoglobin and progressive reduction in weight, as well as improvement in some 
cardiovascular risk factors (36). 
Gastric Bypass Surgery and Gut Secreted Hormones 
Gastric bypass surgery promotes effective and sustained weight loss. This surgery 
accelerates the delivery of nutrients to the hindgut, which results in decreased gastric emptying 
and gastrointestinal transit, dubbed the "ileal brake." GLP-1 and PYY have been suggested as 
mediators of the "ileal brake." Both GLP-1 and PYY release are augmented after gastric bypass 
surgery and have been shown independently to decrease food intake in humans.  Hunger was 
decreased and satiety increased with increases in plasma GLP-1 and PYY. Thus, increased 
postprandial plasma GLP-1 and PYY after gastric bypass surgery may decrease food intake. 
GLP-1 increases insulin and decreases glucagon secretion and thus helps maintain normal blood 
glucose responses (37).  
To determine whether gastric bypass surgery alters PYY levels or response to glucose, a 
study was designed by including 6 obese patients that had undergone gastric bypass surgery, 5 
lean controls and 12 obese controls. Serum PYY levels after a 75-gram oral glucose tolerance 
test was measured. After substantial body weight loss induced by gastric bypass, the PYY 
response to an oral glucose tolerance test was found significantly higher in obese subjects that 
had gastric bypass surgery than the controls and obese subjects not having gastric bypass surgery 
(p <0.01). Thus gastric bypass results in a more robust PYY response to caloric intake. These 
findings provide further evidence for a role of gut-derived hormones in mediating appetite 
changes after gastric bypass, and also support further efforts to determine whether PYY[3–36] 
replacement could represent an effective therapy for obesity (38). 
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All studies discussed above whether on RS or PYY/GLP-1 administration exogenously or 
exenatide treatment or gastric bypass surgery, agree on one point that PYY and GLP-1 hormones 
play roles in food intake and body weight regulation. Among all of these treatments, our resistant 
starch supplementation is a natural way for secretion of these anti-obesity hormones: PYY and 
GLP-1. Theoretically it could also be possible that PYY produced from the gut conveys the 
message to the hypothalamus to suppress the hunger by down regulating the agouti related 
protein (AgRP) and neuropeptide Y (NPY) and by up regulating propiomelanocortin (POMC) 
hormone in the ARC of the hypothalamus (39). Our lab’s gene array results presented at 
Experimental Biology 2007 conference also showed that not only PYY and GLP-1, but a cluster 
of other genes, including genes for other secreted peptide hormones, neurotransmitters, immune 
factors and genes involved in prevention of cancer were also differentially expressed in RS fed 
rats compared to the rats fed an energy control diet containing cellulose, a non fermentable fiber. 
These results support that fermentation is the key factor for the increased signaling in RS fed rats. 
Thus, the up- and down-regulated genes for secreted peptides, neurotransmitters and immune 
factors in RS rats may play roles in improved local health of the GI tract and the health of the 
entire organism with possible benefits of reduced risk for obesity, diabetes, heart disease and 
cancer (40). It was also mentioned earlier that RS fed rats had consistently elevated plasma levels 
of PYY and GLP-1 compared to the rats fed non fermentable fiber (23). Thus, feeding RS is a 
natural way for endogenous secretion of these anti-obesity hormones: PYY and GLP-1, and 
could be a novel approach for the treatment of obesity. 
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CHAPTER 3 
RESISTANT STARCH DOES NOT REDUCE BODY FAT IN RATS FED A HIGH FAT DIET 
Introduction 
Obesity and overweight status continue to be leading public health concerns in the United 
States over several decades and its prevalence has been rapidly increasing in the United States, as 
well as other countries, over the past two decades (1). According to 2003-2004 data, 17.1% of 
US children and adolescents were overweight and 66.3% of adults were overweight or obese (2). 
Obesity has been associated with a relative increase in diabetes, cardiovascular disease, various 
cancers, respiratory disorders during sleep, gallbladder disease, and osteoarthritis (4). Adverse 
health effects of obesity justify the need to discover effective treatments, among them possible 
dietary treatments.  
Resistant starches (RS) contain varying amounts of starch that resist amylase digestion in 
the small intestine and this resistant starch is fermented to short chain fatty acids (SCFA) by the 
microflora in the large intestine (6,7). Thus, adding resistant starches to the diet is the same as 
adding fermentable fiber. Effects of dietary resistant starch include: reduction of metabolizable 
energy density, a bulking effect and fermentation (10). In a previous study, our research group 
controlled for reduction of energy density with the use of cellulose in an energy control diet. The 
rats fed a low fat diet with resistant starch had reduced body fat compared to rats fed an energy 
control diet (10). The results point to increased energy expenditure as a result of the bulking 
effect and/or fermentation because energy intakes were not different.   
Feeding resistant starch was associated with increased SCFA in cecal contents, increased 
mRNA expression of PYY and proglucagon in the cecum of rats, and increased plasma PYY (10) 
and plasma GLP-1 (14). Therefore, fermentable resistant starch may decrease the body fat via 
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increases in SCFA in the large intestine, which appear to stimulate mRNA expression of PYY 
and proglucagon genes by large intestinal cells and increases in PYY and GLP-1 secretion by 
these cells.  
There is some debate about the benefits of higher levels of dietary fat and effectiveness of 
weight loss (41,42). High fat diets with resistant starch replacing regular starch may be effective 
in weight loss. Thus, this current study was conducted to examine the effects of resistant starch 
(RS) in a higher fat diet (28% of energy) on gut signaling and body fat. 
Materials and Methods 
Design. The study used a randomized experimental design with three groups, and was 
undertaken to examine the effects of resistant starch in a high fat diet (28% of energy) on body 
weight, abdominal fat, cecal weight, cecal content pH, plasma PYY and gene expression for 
PYY and proglucagon in male Sprague Dawley rats. The three experimental groups included an 
EC (energy control) group, a RS (resistant starch) group, and a FC (fiber control) group. The 
study required 2 control groups because the independent variables, energy and fiber, were 
confounded by each other. Rats were fed the diets for 10 weeks. 
Animals. Forty-two, 8 week old male Sprague Dawley rats, from the same colony and 
matched for age and weight, were purchased from Harlan Co. (Indianapolis, IN), for use in the 
study. The study protocol was approved by the Louisiana State University Institutional Animal 
Care and Use Committee. The rats were housed individually in wire cages that each contained a 
food cup and a water bottle. The rats were acclimated for one week to recover from travel and to 
habituate to a control powdered diet. Each group of rats was fed its respective treatment diet for 
10 weeks. The 42 rats were randomly assigned to three groups (n=14), and the initial body 
weight of the rats ranged from 281g to 285g. After 10 weeks of the study, the rats were killed. 
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Food intake, food spillage and body weight were recorded three times a week (Monday, 
Wednesday and Friday) for the entire length of the study.  
Diet Preparation. The three diets included AIN93-G recommendations for 
macronutrients, micronutrients and protein (Table1). Specific treatment differences of the three 
diet groups were: EC (Starch source was 100% amylopectin, 11% cellulose fiber by weight, diet 
energy value was 3.7 kcal/g), RS (Starch source was 60% amylose and 40% amylopectin, with 
30% resistant starch and 31% fiber, diet energy value was 3.7 kcal/g), and FC (Starch source was 
100% amylopectin, 31% cellulose fiber, diet energy value was 2.9 kcal/g). Lard and soybean oil 
(2:1) were used as the fat source. 
Sample Collection. The GI tract was removed and weighed, and the disemboweled body 
weight was determined from the mass of the GI tract subtracted from the final body weight of the 
rats. The full ceca were weighed, the cecal contents were removed, the the ceca were rinsed with 
.9% saline, and the empty ceca were again weighed.  Cecal contents were frozen for later pH 
measurement. Epithelial cells were scraped from the cecum and frozen using liquid nitrogen for 
later extraction of total RNA and gene expression for PYY and proglucagon. Abdominal fat 
(retroperitoneal), perirenal fat and epididymal fat were dissected and weighed.  Blood plasma 
was collected for analysis of PYY. After weighing, all materials, except blood and cecal 
scrapings, were added back for proximate analysis of body fat. 
Sample Analysis. Thawed cecal contents were homogenized in distilled water (0.5 g wet 
sample to 5 ml water), and the pH was measured using a combination electrode. Plasma PYY 
was measured using a commercial kit (Phoenix, Belmont, CA).  Whole body fat was determined 
by proximate analysis. An RNeasy mini kit was used for the total RNA extraction from the 
cecum cells for each rat. Gene expressions for PYY and proglucagon were quantified by Real 
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Time Reverse Transcriptase- Polymerase Chain Reaction (real time RT-PCR). Cyclophilin 
mRNA levels from each sample were used as an internal control to normalize the mRNA levels. 
We have determined that cyclophilin, a common housekeeping gene, does not change with our 
treatments. The sequences of TaqMan probes and primers for cyclophilin (GenBank no. 
M15933) and PYY (M17523) are available on request. The probe and primers for proglucagon 
(NM_012707, assay ID Rn00562293_ml) were purchased from Applied Biosystems (Foster 
City, CA). Results for PYY and proglucagon were expressed as a ratio to cyclophilin.  
Statistical Analysis. The data were analyzed using the Statistical Analysis Systems (SAS) 
statistical software package version 9.1. Data were statistically analyzed by using multiple 
univariate ANOVAs followed by F protected least significance difference. The independent 
variable was diet; it had 3 levels: EC, RS and FC. All data were presented as least square means 
(lsmeans) ± pooled SE. Both F-test in ANOVA and least square differences were considered 
significant if p<0.05. 
Results  
There were no differences in disemboweled body weight, abdominal fat, epididymal fat, 
perirenal fat and total fat between EC and RS rats. RS rats had a higher disemboweled body 
weight (p<0.007), abdominal fat (p<0.0006), epididymal fat (p<0.0012), perirenal fat (p<0.003) 
and total fat (p<0.0003) compared to the FC rats; and EC rats also had a higher disemboweled 
body weight (p<0.001), abdominal fat (p<0.0069), epididymal fat (p<0.0317) and total fat 
(p<0.0088) compared to the FC rats. RS rats had significantly lower pH (p<0.0001) and higher 
cecal weights (p<0.0001) compared to EC and FC rats, and there were no differences in pH and 
cecal weight between EC and FC rats (Table 2). EC, FC and RS groups were not significantly 
different in their percent body fat (Fig 1).  
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Plasma PYY was greatest for RS rats (p<0.0001) compared to EC and FC rats, and there 
was no difference in plasma PYY between EC and FC rats (Fig 2A). RS rats had increased gene 
expressions for PYY (p<0.0001) and proglucagon (p<0.0001) compared to EC and FC rats. EC 
and FC rats were not significantly different in PYY and proglucagon gene expressions (Fig 2B 
and 2C).  
Discussion 
RS, one type of non-digestible, fermentable fiber, has three major effects when included 
in the diet: dilution of dietary metabolizable energy, a bulking effect similar to non-fermentable 
fiber, and fermentation to short-chain fatty acids and increase in the expressions of PYY and 
proglucagon (a gene for GLP-1) in the gut (7,8,10,14,20). PYY and GLP-1 are the 
gastrointestinal-derived hormones released post-prandially in proportion to the amount of 
calories ingested (31). PYY reduces food intake and body weight in rodents and suppresses 
appetite and food intake when intravenously infused into humans. GLP-1 peripheral 
administration reduces gastric emptying, food intake and body weight in both rodents and 
humans (31).  
The primary objective of our study was to examine the effects of RS in a high fat diet 
(28% of energy) on gut signaling and body fat. Our results showed that rats fed with RS in a high 
fat diet had increased gene expression for PYY and proglucagon in cecal cells and plasma PYY 
compared to rats fed EC and FC diets. The relative proportion of gene expression for PYY and 
proglucagon, and plasma PYY levels in the EC group compared to the RS group were 19.9%, 
19.2% and 1.28%, respectively. These proportions were similar to those in our low fat diet (18% 
of energy) study (10). Thus, the signaling from the gut is similar with feeding RS in both a low 
and high fat diet.  
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Table 1. Diet Table 
Nutrient 
EC (3.7kcal/g) RS (3.7kcal/g) FC (2.9kcal/g) 
%(g/100g) %(kcal/g) %(g/100g) %(kcal/g) %(g/100g) %(kcal/g) 
Protein 20 20 20 20 20 20 
Tot. carbs 57 53 68 53 39 47 
Fat 12 28 12 28 9 28 
RS 0 0 30 22 0 0 
Cellulose 11 0 31 0 31 0 
Sugar 10 11 10 11 10 14 
EC, Energy control; RS, Resistant starch; FC, Fiber control; Tot carbs, total carbohydrate 
 
 
 
 
Table 2. Measurements from the End of the Study 
LS means measurements EC RS FC SE 
Disemboweled BW (g) 396.5a 388.3a 356.8b 7.61 
Empty cecum (g) 0.682a 2.19b 0.722a 0.07 
pH, cecal contents 8.27a 6.23b 8.21a 0.072 
Abdominal fat (g) 2.81a 3.05a 2.14b 0.159 
Epididymal fat (g) 4.55a 4.92a 3.98b 0.176 
Perirenal fat (g) 1.21ab 1.36a 1.00b 0.075 
Total fat (g) 8.56a 9.34a 7.12b 0.357 
EC, energy control; FC, fiber control; RS, resistant starch; SE, standard error; BW, body weight. 
Measures for treatments across rows with different superscripts are different (p<0.05). 
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Fig 1. Percent Body Fat for Rats. Data presented as lsmeans ± pooled SE. There was no 
significant difference among the groups. 
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Fig 2. Plasma PYY for Rats (A), PYY Gene Expression in Cecum (B), and Proglucagon Gene 
Expression in Cecum (C). *: RS is significantly different than EC and FC at p<0.05. Data 
presented as lsmeans ± pooled SE. 
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RS in a high fat diet resulted in a decrease in pH of cecal contents and an increase in 
cecal weights compared to the other treatment groups.  These results are also consistent with 
other studies on different types of resistant starches (7,24-27,43) and with our group’s previous 
study with RS in a low fat (18% of energy) diet (10). Lower pH and increased cecal weights are 
associated with increased fermentation by RS, and we believe fermentation in the large intestine 
leads to the increased secretion of gut hormones and reduced body fat (10).  
RS did not reduce disemboweled body weight, abdominal fat, perirenal fat, epididymal 
fat and total percent body fat for rats on the high-fat diet in this study compared to our previous 
study with a low fat diet (10). These results are contradictory to our previous study results.  
In our previous study an increased expression of PYY and proglucagon genes in cecum 
and increased secretion of gut hormones was associated with a reduction in body weight and 
body fat in rats fed RS in a low fat diet (10). We have also observed a constant elevation of both 
plasma GLP-1 and PYY in RS fed rats compared to EC fed rats (J. Zhou, M.J. Keenan, M. 
Hegsted, R. Tulley, S.C Danna, A.M. Raggio, K.L. McCutcheon, L. Shen, S. Tripathy, R.J. 
Martin, unpublished data). The results of our current study with resistance to an endogenous 
physiological dose of PYY and GLP-1 with feeding a high fat diet would be similar to the effect 
on leptin, another satiety signal (42,44,45). Thus, the high fat appears to be blunting the response 
to PYY and GLP-1 signaling caused by dietary RS. It is also possible that high fat may be 
increasing ghrelin levels or affecting other signals such as immune factors, neurotransmitters and 
secreted peptides. Many studies on pharmaceutical administration of PYY [3-36] in mice fed a 
high fat diet also reported an increased fat oxidation (12,33) and satiety and administration of 
GLP-1 in humans fed a high fat diet reported a deceased energy intake and increased satiety (30). 
Although our results are contradictory to their results, in their study the doses of PYY and GLP-1 
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infused were much higher. In the current study, our blood level for PYY in RS fed rat was 
1.25pg/100µl, whereas, in infusion studies of PYY, blood levels ranged from 16.2pg/100µl to 
19.8pg/100µl in high fat diet fed mice (33) and 4ng/100µl in pig (46). Thus, effectiveness of 
infused PYY with high fat feeding appears to be due to non-physiological blood levels. 
A report by Cani et al. (2005) demonstrated lower body weight and less body fat with 
oligofructose fermentable fiber in a high fat diet compared to a control high fat diet (13). Though 
their results also appear to be contradictory to our results, in their study dietary energy density 
was not controlled (4.1 vs. 4.4 kcal/g). This may possibly account for the differences in the study 
by Cani et al. and our study. In the current study and in two of our previous studies, our research 
group demonstrated the importance of dietary energy density with a high fat diet (10,29). 
Lowering the energy density of the high fat diet with non-fermentable cellulose for the FC group 
was very effective in lowering body weight and body fat.  
In summary, the study demonstrated that resistant starch in a high fat diet did not reduce 
body fat and body weight. This was contrary to our previous study with a low fat diet. However, 
signaling produced by the gut was similar for both the current study and previous low fat study. 
The possible explanation for this result is that a high fat diet alters the brain response to the 
satiety signals from the gut. This would be similar to the effect on leptin, another satiety signal. 
Thus, the high fat is blunting the response to PYY and GLP-1 signaling caused by dietary RS. 
This result would support the advocacy of RS diets lower in fat content. Future studies should be 
done by adding RS to high fat diets with different types of fat and measuring possible blunting of 
signaling in the brain.  
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CHAPTER 4 
CONCLUSION 
Obesity and overweight are serious health concerns where a person accumulates an 
abnormally high proportion of body fat. This condition can increase the risk of diabetes, 
dyslipidemia, hypertension and osteoarthritis. According to 2003-2004 data, 17.1% US children 
and adolescents were overweight and 66.3% of adults were overweight or obese (2). Obesity 
results from excessive calorie intake and inadequate expenditure of energy. Theories to explain 
this condition include hypothalamic dysfunction of hunger and satiety centers, abnormal 
absorption of nutrients, and impaired action of gut and growth hormones and of hormonal 
regulators: insulin and leptin. The increased incidence of obesity and its associated health risks 
justify the need to discover effective treatments, among them possible dietary treatments. 
It has been suggested that sufficient fiber in the diet will tend to prevent excessive food 
intake and fat accumulation by decreasing the caloric density of the diet, by slowing rate of food 
ingestion, by increasing the effort involved in eating, by promoting intestinal satiety, and by 
interfering slightly with the efficiency of energy absorption. However, fiber is a complex entity 
that includes fermentable and non-fermentable compounds. Resistant starches are non-digestible 
fibers that resist, to varying degrees, amylase digestion in the small intestine and are fermented 
to short chain fatty acids which lead to decrease in pH by the microflora in the large intestine. 
The major SCFA produced include butyrate, acetate and propionate. It is believed that these 
SCFAs, in particular, mediate many potential physiological effects such as improved glycemic 
and insulinaemic responses, improved bowel health, improved blood lipid profile, increased 
satiety and reduced energy intake, increased micronutrient absorption and thermogenesis. All 
these factors may be helpful in preventing diseases such as colorectal cancer, cardiovascular 
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disease, osteoporosis and obesity and assist in the management of diabetes, impaired glucose 
tolerance, inflammatory bowel diseases, diverticulosis and constipation. 
Based on unpublished data from our lab, we believe butyrate is the key SCFA produced 
by fermentation of RS and appears to increase the secretion of gut peptides: peptide YY (PYY) 
and glucagon like peptide 1 (GLP-1). These hormones, in turn regulate energy expenditure. 
Previous data from our lab reported that RS in a low fat diet (18% of energy) increases the 
mRNA expression of PYY and proglucagon genes in cecum and also increases plasma PYY and 
GLP-1 and reduces the body fat (10,14,23). Thus, dietary treatment with RS, a novel approach, 
may be helpful in reducing body fat and obesity.  
Many people consume high fat diets and high fat diets have been promoted for weight 
loss (47). Therefore, in this study, we tested the effects of resistant starch on gut signaling, body 
fat and body weight in male Sprague Dawley rats fed a high fat diet (28% of energy). In our 
study we had three experimental groups: an EC (energy control) group, an RS (resistant starch) 
group, and an FC (fiber control) group. Each had 14 rats. The study required 2 control groups 
because two of the independent variables, energy and fiber, were confounded by each other. Rats 
were fed the diets for 10 weeks. The three diets included AIN93-G recommendations for macro- 
and micronutrients as well as protein (48). 
We found that RS increased the cecum weight and reduced the pH of the cecal contents. 
This is evidence for increased fermentation in the large intestine. RS also increased the plasma 
PYY levels and cecal cell gene expressions for PYY and proglucagon compared to the EC and 
FC groups. This gut signaling was similar to our lab’s earlier study on RS in a low fat diet (18% 
of energy). However, RS did not reduce disemboweled body weight, abdominal fat, perirenal fat, 
epididymal fat, total percent body fat for rats fed a high-fat diet in this study compared to the 
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controls. The possible explanation for this result is that a high fat diet alters the brain response to 
the signals from the gut. This would be similar to the effect on leptin, another satiety signal 
(42,44,45). Thus, the high fat is blunting the response to PYY and GLP-1 signaling caused by 
dietary RS. 
A report by Cani et al. (2005), however, demonstrated lower body weight and less body 
fat with oligofructose fermentable fiber in a high fat diet compared to a control high fat diet (13).  
Their results appear to be contradictory to our results, but in their study, energy density was not 
controlled (4.1 vs. 4.4 kcal/g). This may account for the differences in the study by Cani et al. 
and our study. We have found in several past studies and in the current study that dilution of the 
energy density of a high fat diet with a non-fermentable cellulose was very effective in lowering 
body weight and body fat (10,29).  
Many studies with pharmaceutical administration of PYY [3-36] in mice fed a high fat 
diet have reported an increased fat oxidation and satiety (12,33). Administration of GLP-1 in 
humans fed a high fat diet also reported a deceased energy intake and increased satiety (30). 
These results are also contradictory to our results, but in their study, the doses of PYY and GLP-
1 infused were much higher than blood levels in our studies. 
The data from the current study demonstrated that resistant starch in a high fat diet was 
not associated with reduced body fat and body weight. These results were contrary to our 
previous study with a low fat diet. There was similar gut signaling in both our low and high fat 
diet studies. The possible explanation for the result with the high fat diet is that a high fat diet 
alters the brain response to the energy balance signals from the gut.  This would be similar to the 
effect on leptin, another energy balance signal. Thus, the high fat is blunting the response to 
PYY and GLP-1 signaling caused by dietary RS. This result would support the advocacy of RS 
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diets lower in fat content. It is possible that different types of fat may have different effects. 
Therefore, future studies should be done by adding RS to diets with different types of fat to 
examine the effects on both brain and gut signaling. Our results also demand further research on 
assessment of gut peptides in obese rats after feeding RS to validate our theory that PYY and 
GLP-1 play a part as anti-obesity hormones. 
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APPENDIX A 
STUDY PROTOCOL 
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APPENDIX B 
INGREDIENTS FOR THE THREE TYPES OF DIETS FOR TOTAL SIX KILOGRAMS 
 
 
                     Ingredients                        Amounts 
 EC                       RS                     FC  
1. Macro mix  
 Amioca cornstarch 
 High maize cornstarch 
2.500kg                -                     1.489kg 
      -                  3.184kg                - 
 Sucrose 0.600kg             0.600kg            0.600kg 
 Cellulose 0.634kg                -                     1.860kg 
 Casein 1.200kg             1.200kg            1.200kg 
2. Micro mix  
    Mineral mix (AIN-93G) 0.210kg             0.210kg            0.210kg 
    Vitamin mix 0.060kg             0.060kg            0.060kg 
    Choline chloride 0.008kg             0.008kg            0.008kg 
    L-Cystine 0.018kg             0.018kg            0.018kg 
3. Oil mix  
 Soybean 0.240kg             0.240kg            0.240kg 
 Crisco or Lard 0.480kg             0.480kg            0.480kg 
 BHT 0.084g               0.084g              0.084g 
 Food coloring ¼ tsp                 ¼ tsp                 ¼ tsp 
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APPENDIX C 
DIET PREPARATION 
To prepare the AIN-93G diet, the macronutrients were weighed and combined in a large 
mixing bowl. The ingredients were mixed for 10 minutes at low speed. The micronutrients were 
sieved sequentially into a bowl, ground up, and added to the macro mix. Both the macro mix and 
micro mix were mixed together for 10 minutes until a uniform distribution of color of micromix 
throughout the mix was obtained. An oil mix was prepared, added to the mixture, and mixed for 
30 minutes. The diet was stored frozen (-200C) in Ziploc bags. Each was labeled with the diet 
type, date, batch number, and initials of the person who prepared the diets. A small sample from 
each diet batch was placed in a tiny plastic bag and labeled for future diet analysis if necessary. 
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APPENDIX D 
PROCEDURE FOR RECORDING FOOD INTAKE AND BODY WEIGHT 
The weight of the food cup plus the food was recorded before and after each feeding. To 
determine the amount of food consumed the differences were calculated.  To weigh the rats, a 
bucket was placed on a balance, the balance was brought to zero, and the rats were individually 
placed in the bucket and weighed. 
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APPENDIX E 
METHOD FOR EXTRACTION OF mRNA FROM CECUM CELLS (QAIGEN KIT)  
An RNeasy mini kit was used for the total RNA extraction from the cecum cells for each 
rat. A small piece of each sample was cut and placed in a tube. Buffer RLT was added to the 
sample piece which was homogenized by using a Rotor-stator homogenizer (Model PCU-11, 
Kinematica). The samples were centrifuged, a supernatant for each sample was collected in a test 
tube, and ethanol was added. A sample of 700µl from the test tube was transferred to RNeasy 
mini column and centrifuged. The liquid collected at bottom of test tube was discarded and then 
700µl buffer RW1 was added to the RNeasy mini column, the samples were centrifuged, and the 
liquid collected was again discarded. In the following step, 500µl buffer RPE was added to the 
RNeasy mini column, the samples were centrifuged, and the liquid was discarded. The final step 
was repeated once. At last RNase free water of 50µl was added to each sample. The samples 
were again centrifuged; the total RNA was collected in a test tube and stored at -800C. 
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APPENDIX F 
DETAILS ABOUT STATISTICAL MODEL 
The independent variable was diet; it had 3 levels: EC, RS and FC. The  10 dependent 
variables were the following: disemboweled body weight of the rats, weight of the empty cecum, 
pH of cecal content, abdominal fat, perirenal fat, epidydimal fat, total percent body fat,  plasma 
PYY level, gene expression for PYY, gene expression for proglucagon. ANOVAs were used to 
analyze overall effects of diets on each dependent variable. The least significance difference 
followed by ANOVA was used to know the individual diet effect on each dependent variable. 
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APPENDIX G 
DATA USED FOR FIGURE 1, 2A, 2B AND 2C 
 
Group      %Body fat      Plasma PYY (pg/100µl)   PYY: Cyclophilin   Proglucagon: Cyclophilin 
EC          14.427 ± 0.6       0.016 ± 0.149                 0.227 ± 0.115           0.821 ± 0.174 
FC          14.234 ± 0.6       0.025 ± 0.149                 0.166 ± 0.115           0.735 ± 0.174 
RS          15.8 ± 0.6           1.25 ± 0.149                   1.14 ± 0.115             4.27 ± 0.174 
All data are presented as lsmean ± pooled standard error 
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